buprenorphine/naloxone sublingual tablet / Aoxing - LARVOL DELTA

[VIRTUAL] Assessment of Opioid Withdrawal with Clinical Opiate Withdrawal Scale Treatment Protocol at A Community Psychiatric Hospital (ASHP 2020) - "Buprenorphine sublingual tablet was the primary choice of medication for the COWS protocol used, with 98 (84%) of patients receiving a dose correlating to their respective COWS scores. For the remainder patients, methadone was administered to 6 (5%), buprenorphine-naloxone sublingual tablets to 2 (2%), a combination regimen of buprenorphine and buprenorphine-naloxone to 1 (1%), and no medication to 10 (8%)... The Clinical Opiate Withdrawal Scale serves as a useful tool in assessing patients with opioid use disorder withdrawal. In the interim analysis, only a small percentage of patients were assessed with the COWS protocol at the frequency as indicated by the opioid withdrawal order set. This demonstrates the need to re-evaluate optimal dosing strategies in opioid use disorder patients or education on the use of the COWS protocol."

Clinical • Psychiatry

BOS: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (clinicaltrials.gov) - P1/2; N=26; Completed; Sponsor: Wayne State University; Recruiting ➔ Completed; Phase classification: P1 ➔ P1/2; N=40 ➔ 26

Enrollment change • Phase classification • Trial completion • Addiction (Opioid and Alcohol) • BDNF • IL1R1

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder. (PubMed, Drugs R D) - "The present data suggest that buprenorphine/naloxone pharmacokinetic profiles in Chinese participants are consistent, overall, with those in Western populations, supporting no differences in dosing."

Journal • PK/PD data

Development and validation of the scale to assess satisfaction with medications for addiction treatment - Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER). (PubMed, Int J Drug Policy) - "These results support the validity and reliability of the SASMAT-BUNHER."

Journal

Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. (PubMed, Asia Pac Psychiatry) - "Efficacy and safety results from this clinical trial support a positive benefit-risk ratio for buprenorphine/naloxone sublingual tablet use in the treatment of an opioid-dependent Chinese population."

Clinical • Journal • P3 data

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men. (PubMed, Addict Health) - "Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics...Moreover, there was no significant difference between the two groups in terms of objective and subjective symptom reduction (P > 0.050). Buprenorphine/naloxone is as effective as buprenorphine in controlling opiate withdrawal symptoms."

Journal

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: University of Vermont; N=200 ➔ 100

Enrollment change